* Directors / Signatories / KMP / Principals

RANBAXY LABORATORIES LTD

Company Status: Amalgamated As on: 06-Aug-2019

D&B Summary

Paid-up Capital(INR)
2,128,317,485
Authorised Capital(INR)
3,000,000,000
Total Charges(INR)
Open Charges(INR)
D&B Reports
Basic Report
INR 6000.00 /-
Report Status : Available
Financial Year : N/A
Quick Check Report
INR 2500.00 /-
Report Status : Available
Financial Year : N/A
Compliance Report
INR 14000.00 /-
Report Status : Available
Financial Year : N/A
Sectoral Risk Outlook (Industry Report)
Sectoral Risk Outlook (Industry Report) Status : Unavailable
Financial Year : NA
Business of interest
Low High
No. of search on company
9
80% Complete
News

Global Inhalation And Nasal Spray Generic Drugs Market Growth Outlook 2015-2027 By- Ranbaxy Laboratories Ltd., Novartis AG (Sandoz International GmbH), Cipla Ltd., Nephron Pharmaceuticals Corporation, Allergan plc - SoccerNurds


Global Imipenem and Cilastatin Sodium Market 2025 by Trends, Strategies and Growth by leading Manufacturers High Science Co.,Ltd., Shenzhen Haibin Pharmaceutical, Savior Lifetec Corporation, Ranbaxy Laboratories, Ranbaxy Laboratories Ltd - The Bisouv Network


Global Alopecia Treatment (Hair Loss) Market 2021: Global Industry Expand with Significant CAGR by 2028|| Top Competitors- Cipla,Viviscal,Dr. Reddy's Laboratories Ltd.,Regaine,Merck & Co., Inc,Ranbaxy Laboratories Ltd - South Florida Theater Review


Global Enalapril Market 2021 Recovering From Covid-19 Outbreak | Know About Brand Players: Apotex Inc, Sandoz Inc, Krka Dd Novo Mesto, Apothecon Inc Div Bristol Myers Squibb, Ranbaxy Laboratories Ltd, etc. | InForGrowth - NeighborWebSJ


Hair Loss and Growth Treatments and Products Market (COVID-19) to Witness Astonishing Growth by Forecast 2021-2027 |Cipla, Viviscal, Regaine, Merck & Co., Inc, etc - NeighborWebSJ


Global Alopecia Market for robust expansion throughout the forecast period 2020-2026 – NeighborWebSJ - NeighborWebSJ


Global API Contract Manufacturing Market Focuses on SWOT analysis, Industry Synopsis, Development Plans 2021 to 2026 – NeighborWebSJ - NeighborWebSJ


Erythropoietin Stimulating Agents Market Future Scenario, Growth rate, Market Segmentation, and Industrial Opportunities to 2027 – The Bisouv Network - The Bisouv Network


Global Alopecia Treatment (Hair Loss) Market Set To Boom With Top Booming Companies-Dr. Reddy's Laboratories Ltd.,Regaine,Merck & Co., Inc,Ranbaxy Laboratories Ltd,Phyto – Alès Groupe - The Courier


Barotrauma Market Advancing the Growth Globally: Market Dynamics, Trends, Efficiencies Forecast 2026 - NeighborWebSJ


Inhalation And Nasal Spray Generic Drugs Market: Industry Analysis And Forecast 2026 – The Bisouv Network - The Bisouv Network


Hair Loss Treatment Products Market Size 2021 | Global Industry Share, Trends, Growth Insights, SWOT Analysis by Top Key Vendors and Forecast to 2027 - The Bisouv Network


Global Enalapril Industry Research Report, Growth Trends and Competitive Analysis 2021-2027| Apotex Inc, Apothecon Inc Div Bristol Myers Squibb, Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa - SoccerNurds


Controversy swirls around India’s homegrown Covid vaccine - Mint


Androgenetic Alopecia Treatment Market will Explore Robust Size & Growth During 2018-2026 – NY Market Reports - NY Market Reports


Generic Drugs Market 2020-2026 By Application, By Product Type, Top Key Players: Ranbaxy Laboratories, Ltd, Actavis, Mylan Inc., Teva Pharmaceutical Industries, Ltd., Dr. Reddy’s Laboratories - The Courier


API Contract Manufacturing Market Size 2021 | Global Industry Analysis, Development, Scope, Trends, Forecast to 2027 – Express Keeper - Express Keeper


Botanical and Plant-Derived Drugs Market 2021 Focusing on Top Key Players like Abbott Laboratories, Eli Lilly, Medigene, Pfizer, Lupin Ltd., Johnson & Johnson, Ranbaxy Laboratories Ltd., Novartis International AG, Glaxosmithkline and Leo Pharma - The Courier


India's Sun Pharma to buy struggling Ranbaxy for $3.2 billion as Daiichi Sankyo retreats - Reuters


U.S. class action asserts India's Ranbaxy manipulated FDA rules - Reuters


Ranbaxy shares to stop trading on exchanges from 6 April - Livemint


Sun Pharma buys Ranbaxy to create generics giant - Livemint


Singapore court rejects Singh brothers' plea against arbitral award in Daiichi case - VCCircle


Ranbaxy Laboratories posts Rs160 crore loss in Dec quarter - Livemint


Global Alopecia Treatment (Hair Loss) Market Regional Overview, Leading Company Analysis And Forecast To 2026 | Dr. Reddy's Laboratories Ltd.,Regaine,Merck & Co., Inc,Ranbaxy Laboratories Ltd,Phyto – Alès Groupe - The Courier


Ex-Ranbaxy owners told to pay Rs2,500 crore for hiding facts in Daiichi sale - Livemint


Six business lessons from the Daiichi–Ranbaxy deal fiasco - Livemint


Ranbaxy pleads guilty, to pay $500 million in U.S. settlement - Reuters


Ranbaxy And The Culture Of Jugaad: What Brought A Leading Company Down - Outlook India


Ranbaxy agrees to $4 billion buyout - Jacksonville Daily Record

Ranbaxy agrees to $4 billion buyout  Jacksonville Daily Record


Ranbaxy to contest US pharma company to protect drug patent - Hindu Business Line


Making Ranbaxy units cGMP compliant time consuming: Sun Pharma - Livemint


How Ranbaxy hurtled towards a meltdown - Livemint


Ranbaxy recalls some batches of generic Lipitor in latest quality blow - Reuters


Ranbaxy scrambles for ingredients to make generic Nexium - Reuters


Sun Pharma sells Ranbaxy divisions to Strides Arcolab for Rs165 crore - Livemint


Daiichi-Ranbaxy row: Delhi HC restrains Singh brothers from using bank a/cs - Livemint


FDA may inspect one Ranbaxy plant in fiscal 2017: Dilip Shanghvi - Livemint


Ranbaxy puts biosimilars into gear - Reuters


Sun Pharma Took Two Years To Integrate Ranbaxy’s Employees - BW Businessworld


FDA Says Ranbaxy Can’t Make Generic Versions of Nexium, Valcyte - Wall Street Journal


Daiichi-Ranbaxy row: HC allows the sale of Singh brothers firms to repay the Rs 3,500 crore arbitration... - Medical Dialogues


Ranbaxy Laboratories posts surprise March-quarter loss on write-offs - indiatvnews.com


Sun Pharma’s Mohali unit violated manufacturing norms, finds US FDA - Livemint


Religare group emerges out of Ranbaxy shadow - Livemint


Ranbaxy gets FDA approval for Novartis's Diovan generic - Reuters India


Ranbaxy fallout: Indian pharma under the microscope - Livemint


Sun Pharma shares soar as Ranbaxy to delist - Livemint


Ranbaxy in licensing pact with Gilead Sciences for HIV drug - Hindu Business Line


Truth behind FDA ban on Ranbaxy found: Human hair embedded in tablet - Firstpost


The rise and fall of Singh brothers' business empire - CNBCTV18


Sun Pharma warns on revenue, profit over Ranbaxy takeover - Livemint


FDA bans imports from Sun Pharma plant in India crackdown - Reuters


Sun Pharma, Ranbaxy shares decline after court stalls merger - Livemint


The CEO who capped a $37 billion recovery with a cancer drug deal - Livemint


Ranbaxy shares crash as Mohali plant comes under FDA scanner - Livemint


Ranbaxy’s US plant gets FDA clearance - Livemint


Competition Commission extends Sun Pharma-Ranbaxy probe to new stage - Livemint


Ranbaxy and Teva settle with NY Attorney General over collusion - Reuters


Sun Pharma hikes stake in Zenotech to 57.56% - VCCircle


Sun Pharmaceutical withdraws suit filed by Ranbaxy against USFDA - Business Today


Culture of 'Bending Rules' in India Challenges U.S. Drug Agency - Bloomberg


All’s Not Well In Sun Pharma-Ranbaxy Human Resource Integration? - BloombergQuint


Ranbaxy Wins Approval for Generic Blood-Pressure Drug Diovan - Wall Street Journal


SC gives Andhra Pradesh HC two days to decide Sun-Ranbaxy issue - Livemint


Petition against Sun Pharma for allegedly violating merger norms - Livemint


Singh brothers, ex-promoters of Ranbaxy held in Rs 740 crore fraud | What the case is all about - Jagran English


FDA bans Ranbaxy’s fourth plant in India - The Hindu


Ranbaxy resumes supply of Atorvastatin tablets in US market - The Hindu


Sun Pharma-Ranbaxy Laboratories deal comes under CCI scanner - indiatvnews.com


Sun Pharma denies wrongdoing, says some issues are factually incorrect - Livemint


Ranbaxy makes good on its promise - Livemint


Pfizer, Ranbaxy win lawsuit over generic Lipitor - Deccan Herald


High Court approves merger of Sun Pharma, Ranbaxy - Equity Bulls


Ranbaxy posts profit in July-Sept quarter - MarketWatch


CCI clears Sun-Ranbaxy deal with some riders - Livemint


Domestic M&As surge to a four-year high in 2014 - Livemint


Fortis shareholders vote out former Ranbaxy CEO Brian Tempest as director - VCCircle


Sun Pharma-Ranbaxy merger: Honeymoon over, now to make it work - Livemint


Ranbaxy Laboratories dips nearly 7% on bourses - Livemint


Ranbaxy’s performance hinges on generic Diovan - Livemint


Ranbaxy accused of gaming FDA rules to thwart rival drug makers - Livemint


Daiichi Sankyo sells entire 8.9% stake in Sun Pharma for $3.18B; Temasek, GIC among buyers - VC Circle


Sun Pharma asked to pay Rs 279 crore GST dues on Ranbaxy arbitration - CNBCTV18


Sobti quits Ranbaxy over differences with management - The Hindu


Ranbaxy Labs Narrows Losses - Wall Street Journal

Ranbaxy Labs Narrows Losses  Wall Street Journal


How Singh brothers got into trouble - bit by bit - Business Today


Singh brothers sent to 14 days judicial custody in Religare case - Livemint


Open offer for Zenotech fails to meet target - Livemint


Sun Pharma-Ranbaxy merger gets BSE, NSE clearance - Livemint


Fortis tries to leave its past behind by seeking to rebrand as Parkway - VCCircle


‘Bottle of Lies’: Book on Generic Drugs ‘Exposes’ Indian Companies - The Quint


Delhi HC allows Daiichi Sankyo to recover Rs3,500 crore from Singh brothers - Livemint


Know 5 things before buying Sun Pharma shares - Economic Times


Andhra HC lifts stay on Sun Pharma-Ranbaxy merger - VC Circle


Ranbaxy case: SC rejects plea by Singh brothers against Daiichi Sankyo’s Rs3,500 crore award - Livemint


FDA bans imports from canadian drugmaker Apotex’s India plant - Livemint


Class Certification Denied in Suit Over Adulterated Ranbaxy Drugs | New Jersey Law Journal - Law.com


Ranbaxy halts drug ingredients shipment from Toansa, Dewas plants - Livemint


Ranbaxy keeps sales forecast as India reviews US court ruling - Livemint


Company Details

CIN.

L24231PB1961PLC003747

ROC Code

RoC-Chandigarh

Date of Incorporation

16/06/1961

D&B D-U-N-S® Number

65-XXX-4795


Company Category

Company limited by Shares

Company SubCategory

Non-govt company

Class of Company

Public

Industry

MANUFACTURING


Authorised Capital( INR)

3,000,000,000

Paid up Capital( INR)

2,128,317,485

Number of Members

0

Registered Address

A-41 Industrial Area Phase VIII-A SAS Nagar PB 160071 IN


Email Id

secretarial@ranbaxy.com

Whether Listed or not

Listed

Last AGM

28/07/2014

Last Balance Sheet

31/03/2014


Registration Number

3747

Location

Potentially Related Company Based on Common Directorship

Charges

Charge Holder Name Assets under charge Charge Amount Date of Creation Date of Modification Status

Principals/Signatory Details

Identification Number Principal Names Designation Begin date End date
00021752 RAJESH VIREN SHAH Director 19/12/2008 13/10/2020
01929668 ARUN SAWHNEY Managing Director 09/05/2011 02/10/2020
02143003 PERCY KEKU SHROFF Director 27/03/2009 22/07/2021
02436813 TAKASHI SHODA Director 19/12/2008 -
02439360 AKIHIRO WATANABE Director 19/12/2008 05/10/2020
02439401 TSUTOMU UNE Director 19/12/2008 13/10/2020
02454431 ANTHONY HUGH WILD Director 19/12/2008 -
03562763 KAZUNORI HIROKAWA Director 09/05/2012 27/06/2012
XXXXXXXXXX SUSHIL KUMAR PATAWARI Company Secretary 21/09/1995 09/12/2016

Corporate Family Connections

Detailed profiles of all businesses owned and operated by this company for insights and prospecting.

51 Subsidiaries


0 Branches


2 Affiliates

Company network based on common directorship

© 2021 - Dun & Bradstreet Information Services India Pvt Ltd. All rights reserved.